In murine models of leukemia, melanoma and ovarian cancer, CXCR4 inhibition, obtained with blocking antibodies or with the CXCR4 antagonist AMD3100, increased the effector to Tregs ratio at the tumor site and reduced tumor growth (298–301). This evidence concerns the gene CXCR4 and neoplasm.